Oncostatin M Is Related to Polycystic Ovary Syndrome-Case Control Study

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Reproductive Medicine

Background:

• Oncostatin M, a novel adipokine, influences oogenesis, lipogenesis, and inflammation.
• Adipokines are implicated in polycystic ovary syndrome (PCOS) pathogenesis and associated metabolic disturbances like dyslipidemia and insulin resistance.

Purpose of the Study:

• To investigate serum oncostatin M levels in women with PCOS compared to controls.
• To explore the correlation between oncostatin M and various hormonal and metabolic parameters in PCOS.

Main Methods:

• A case-control study involving 32 PCOS patients and 32 controls.
• Analysis of serum levels of glucose, insulin, lipids, inflammatory markers, hormones (TSH, LH, FSH, testosterone, prolactin, estradiol), and oncostatin M.
• Calculation of homeostasis model assessment of insulin resistance (HOMA-IR).

Main Results:

• Significantly lower oncostatin M levels and higher C-reactive protein levels were observed in the PCOS group.
• Oncostatin M showed inverse correlations with total cholesterol, non-HDL cholesterol, fasting glucose, LH/FSH ratio, C-reactive protein, HOMA-IR, and LDL cholesterol.
• No significant correlation was found between oncostatin M and total testosterone.

Conclusions:

• Plasma oncostatin M levels are significantly reduced in women with PCOS.
• Lower oncostatin M levels are associated with key hormonal and metabolic derangements characteristic of PCOS.
• Oncostatin M presents a potential novel therapeutic target for managing PCOS and its metabolic complications.